Ideal candidates for semaglutide include: Adults with type 2 diabetes (Ozempic and Rybelsus) Adults who have established heart and blood vessel-related disease or those who are at risk of developing these diseases or heart failure (Ozempic) Adults with chronic kidney disease and type 2 diabetes, to reduce the risk of worsening kidney disease or end-stage renal disease (Ozempic) Children aged 12 or more, adolescents, and adults with obesity (BMI 30 or more) and overweight (BMI 27 or more) with at least one weight-related complication, such as hypercholesterolemia, hyperlipidemia, heart disease, and hypertension (Wegovy) Patients with metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver scarring or fibrosis, but they should not have cirrhosis (Wegovy) Head-to-head comparison: Metformin vs
No published human clinical trial exists
Informed consent Received from patient
El responsable del tratamiento concede gran importancia a su privacidad y trata sus datos personales de conformidad con el Reglamento general de proteccin de datos de la Unin Europea relativo a la proteccin de las personas fsicas en lo que respecta al tratamiento de datos personales (en lo sucesivo denominado RGPD), as como con cualquier legislacin futura o adicional que lo aplique, cuando sea aplicable
Nausea, constipation, and reduced appetite are common but typically temporary
Inappropriate major histocompatibility complex class II expression by thyroid follicular cells in thyroid autoimmune disease and by pancreatic beta cells in type I diabetes
